MET

Hepatocyte growth factor receptor · P08581 · MET on Sugi Atlas →

272,574 patent compounds predicted against MET, 173,834 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Mk-2461 Mk-2461 (SCHEMBL93526) 1.00 20/20
Pf-04217903 Pf-04217903 (SCHEMBL93550) 1.00 20/20
SCHEMBL104141 SCHEMBL104141 0.82 20/20
SCHEMBL105700 SCHEMBL105700 0.82 20/20
SCHEMBL104578 SCHEMBL104578 0.77 20/20
SCHEMBL105701 SCHEMBL105701 0.75 20/20
SCHEMBL106402 SCHEMBL106402 0.74 20/20
SCHEMBL106456 SCHEMBL106456 0.72 20/20
SCHEMBL105699 SCHEMBL105699 0.71 20/20
SCHEMBL105698 SCHEMBL105698 0.70 20/20
SCHEMBL106728 SCHEMBL106728 0.70 20/20
SCHEMBL108517 SCHEMBL108517 0.70 20/20
SCHEMBL104160 SCHEMBL104160 0.69 20/20
Glesatinib Glesatinib (SCHEMBL106319) 1.00 19/20
SCHEMBL141721 SCHEMBL141721 0.81 19/20
SCHEMBL104760 SCHEMBL104760 0.78 19/20
SCHEMBL139114 SCHEMBL139114 0.74 19/20
SCHEMBL106729 SCHEMBL106729 0.73 19/20
SCHEMBL106325 SCHEMBL106325 0.69 19/20
SCHEMBL141854 SCHEMBL141854 0.67 19/20

Clinical trials — most relevant to MET by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC. PHASE4COMPLETED
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy PHASE1/PHASE2COMPLETED
Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies PHASE1/PHASE2COMPLETED
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases PHASE2COMPLETED
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer PHASE1/PHASE2COMPLETED
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer PHASE2COMPLETED
Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET PHASE2COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure PHASE1/PHASE2RECRUITING
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) PHASE2RECRUITING
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck PHASE2COMPLETED
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma PHASE2COMPLETED
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) PHASE2RECRUITING
A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer PHASE2COMPLETED
Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas PHASE2COMPLETED
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma PHASE2COMPLETED
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) PHASE2COMPLETED
Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer PHASE2COMPLETED
A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer PHASE1/PHASE2RECRUITING
Pazopanib and ARQ 197 for Advanced Solid Tumors PHASE1COMPLETED
A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma PHASE1COMPLETED
First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors PHASE1COMPLETED
Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer PHASE1COMPLETED
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors PHASE1COMPLETED
A Phase I Trial of HS-10241 in Solid Tumors PHASE1COMPLETED
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status PHASE1UNKNOWN
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer nanUNKNOWN
Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma nanCOMPLETED
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MET binder may also engage these)

ProteinNameSimilarity
A0M8R7 1.000 A0M8R7 →
Q09YH7 1.000 Q09YH7 →
Q07DZ1 1.000 Q07DZ1 →
Q09YN5 1.000 Q09YN5 →
Q75ZY9 1.000 Q75ZY9 →
Q769I5 1.000 Q769I5 →
Q2QLA9 1.000 Q2QLA9 →
Q09YK0 1.000 Q09YK0 →
Q108U6 1.000 Q108U6 →
Q00PJ8 1.000 Q00PJ8 →
Q2QLH6 1.000 Q2QLH6 →
Q07E01 1.000 Q07E01 →
Q2IBD8 1.000 Q2IBD8 →
Q2QLF1 1.000 Q2QLF1 →
Q2IBF2 1.000 Q2IBF2 →
Q2QLC0 1.000 Q2QLC0 →
Q2QLG5 1.000 Q2QLG5 →
A1X150 1.000 A1X150 →
Q2IBA6 1.000 Q2IBA6 →
Q07E37 1.000 Q07E37 →
Q2IBC0 1.000 Q2IBC0 →
Q09YI9 1.000 Q09YI9 →
P97523 1.000 P97523 →
Q07DY1 1.000 Q07DY1 →
Q07DV8 1.000 Q07DV8 →
P16056 1.000 P16056 →
Q2IBG7 1.000 Q2IBG7 →
Q2QLE0 1.000 Q2QLE0 →
Q07E48 1.000 Q07E48 →
Q07E24 1.000 Q07E24 →